Track topics on Twitter Track topics that are important to you
Biogen Incorporated PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Biogen Incorporated articles that have been published worldwide.
We have published hundreds of Biogen Incorporated news stories on BioPortfolio along with dozens of Biogen Incorporated Clinical Trials and PubMed Articles about Biogen Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Incorporated Companies in our database. You can also find out about relevant Biogen Incorporated Drugs and Medications on this site too.
Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion molecule 1, LPAM-1) integrins, is approved for the treatment of Multiple sclerosis (MS) and Crohn's disease (CD). NAT has been well tolerated in pivotal trials. Progressive multifocal leukoencephalopathy (PML) is an uncommon but serious complications resulting from NAT treatment. It is not confirmed that higher NAT...